Cheiron Raises $8M Seed for AI Drug Development Platform

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Cheiron, an AI company based in Los Altos, California, has raised an $8 million seed round to build an operating system for drug programs. Menlo Ventures led the round, which the company announced on July 22, 2026.

The financing drew a notable group of backers, including Moderna co-founder and MIT Institute Professor Robert Langer, former Pfizer chief medical officer Freda Lewis-Hall, Chai Discovery co-founder and chief executive Josh Meier, former Starbucks chief executive Laxman Narasimhan, and former Apple AI chief John Giannandrea.

Founded in 2024 by Stanford-trained AI researchers and biopharma operators, Cheiron is building what it calls the first AI-native operating system that represents an entire drug program as a single connected system. In less than six months since launch, the company says its platform has been adopted by tens of thousands of biopharma professionals and put to work by major drug developers.

Cheiron plans to use the capital to speed up development of its Life Sciences Knowledge Graph, extend the platform across clinical, regulatory, and strategic workflows, and grow its engineering, product, and life sciences teams.